Preview: India's Sun Pharmaceutical inches higher ahead of Q1 results
BUZZ-PREVIEW-India's Sun Pharmaceutical inches higher ahead of Q1 results ** Shares of Sun Pharmaceutical Industries SUN.NS rise 0.6% to 2,013.10 rupees
** Analysts on avg expect pharmaceuticals co to post a 31.2% Y/Y growth in Q1 consol net profit to 29.9 bln rupees ($312.5 mln)
** Analysts on avg expect SUN's consol revenue to rise 11.8% y/y to 155 bln rupees
** Brokerage ICICI Securities expects revenue growth to be led by steady traction in India formulations and scale-up in specialty portfolio
** HDFC Securities says US generic business is expected to remain flat Q/Q, sharp decline Y/Y due to absence of gRevlimid
** PL Capital says revenue growth to be led by specialty and domestic segments with moderate EBITDA growth
** PhillipCapital says margins to decline to 26.8% on account of speciality related launch cost in the US
** YTD, SUN up 17.1% vs pharma index's .NIPHARM ~17% rise
($1 = 95.6800 Indian rupees)
(Reporting by Vijay Malkar and Kashish Tandon)
Recent news on Sun Pharmaceutical Industries
See all newsROI-US blue wave reshapes Asia's winners and losers: Manishi Raychaudhuri
Brief: Sun Pharma Clarifies Regarding News Report Relating To Company's Assam Facility
Street View: India's Sun Pharma Organon buy, psoriasis drug are risk factors
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses